Isocitrate dehydrogenase 1: what it means to the neurosurgeon
Year: 2013
Type: review
Abstract: Isocitrate dehydrogenase 1 (IDH1) mutations have been discovered to be frequent and highly conserved in secondary glioblastoma multiforme and lower-grade gliomas. Although IDH1 mutations confer a unique genotype that has been associated with a favorable prognosis, the role of the mutated IDH1 enzyme and its metabolites in tumor initiation and maintenance remains unresolved. However, given that IDH1 mutations are homogeneously expressed and are limited solely to tumor tissue, targeting this mutation could potentially yield novel treatment strategies for patients with glioblastoma multiforme.
Source: Journal of neurosurgery
Institutions: Duke University, Duke Medical Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells, Clinical Neuroimmunology of Vaccines in Brain Tumors, NINDS Research Education Programs for Residents and Fellows in Neurosurgery, G3199277650, G4050337649, G53543037, SRC on Primary Tumors of the CNS, G7068294288, G8185792080
OpenAlex ID: W1557898514